Albireo: Albireo Gets FDA Priority Review of Bylvay in Alagille Syndrome

(marketscreener.com) By Colin Kellaher Albireo Pharma Inc. on Tuesday said the U.S. Food and Drug Administration granted priority review to its application seeking expanded approval of its Bylvay drug for patients with the rare liver disease Alagille syndrome. The Boston biopharmaceutical company said FDA approval would more than double the market...https://www.marketscreener.com/quote/stock/ALBIREO-PHARMA-INC-31816183/news/Albireo-Gets-FDA-Priority-Review-of-Bylvay-in-Alagille-Syndrome-42984035/?utm_medium=RSS&utm_content=20230214